Haystack MRD® by Quest Diagnostics®

Haystack MRD® is an advanced tumor-informed minimal residual disease (MRD) test that detects ctDNA in blood with exceptional sensitivity and specificity.

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

If you’re attending #ESMO26, don't miss poster presentations featuring Haystack technology.

Check out a sneak preview: https://t.co/fz8Y3UDZVQ  

#ctDNA #MRD #oncology

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Going to #ESMO26 in Madrid? Interested in the advanced version of the technology featured in DYNAMIC? How about a #ctDNA test with zero false positives in clinical studies to date? 
Visit Quest Diagnostics booth 8002 to learn about Haystack MRD®. 
https://t.co/PtOeW2BtJI
#MRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

New peer-reviewed study! The Journal of Molecular Diagnostics recently published a Haystack MRD® clinical validation study using all samples with available DNA from the landmark DYNAMIC trial.   

Check out our press release (https://t.co/YOBPRN32bY)

#ctDNA #MRD #oncology

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Announcing the launch of a pilot program between Haystack MRD® by Quest Diagnostics® and OncoEMR®! Select providers now have access to Haystack MRD via OncoEMR MPI, bringing increased confidence in clinical decision-making. https://t.co/Flrfq3ljHf

#ctDNA #MRD #oncology

[Quest Diagnostics @QuestDX]

We're proud to announce that Quest Diagnostics is now the largest clinical reference lab to integrate oncology tests in OncoEMR using the opt-in OncoEMR Molecular Profiling Integration (MPI) ordering feature.

Read more: https://t.co/wwpVacZgBx

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

A major milestone for Haystack MRD® by Quest Diagnostics®: New York State approval is another proof point for the quality and technological sophistication of our ctDNA test for solid tumors.

Read more: (https://t.co/axFcY6MqVp)

#ctDNA #MRD #oncology

[Quest Diagnostics @QuestDX]

A significant milestone for Haystack MRD® by Quest Diagnostics® and the patients we serve. With New York State approval, @HaystackMRD is now available in all 50 U.S. states, helping expand access to advanced cancer monitoring. https://t.co/pgS9a5VEVa

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Did you hear? Haystack MRD® is now approved by New York State. This approval is a prestigious regulatory milestone, underscoring Haystack MRD’s exceptional performance in detecting residual or recurrent cancer. 

Learn more: (https://t.co/Nkw09XdOZf)

#ctDNA #MRD #oncology

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

✅ Approved! We’re thrilled to announce Haystack MRD® by Quest Diagnostics® is approved by New York State. This broadens patient access to Haystack MRD, as it's now available in all 50 US states.  

Check out our press release: (https://t.co/KNi5u4ubSP) 

#ctDNA #MRD #oncology

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

One of our #ASCO26 posters (532) shows high concordance between ctDNA and ctHPV-DNA in HPV-driven oropharyngeal cancers, with ctDNA clearing faster than HPV in patients who were undergoing treatment. Learn more: https://t.co/SElQkOQxnC #ctDNA #MRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Heading to #ASCO26? Visit our poster on ptDNA in gastroesophageal cancer to see how next-generation sequencing is being used in innovative ways to advance personalized care. May 30, 9:00 AM-12:00 PM, poster 84. https://t.co/KRs7Lzaw9U #ctDNA #MRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Research collaborators are presenting new data at ASCO using Haystack MRD in 2 new disease types – gastric cancer and head and neck cancer.

Learn more about the abstracts being presented and meet Confidence, your Haystack Hero. https://t.co/VnWKtOQqli

#ASCO26 #ctDNA #MRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Confidence changes how you move forward in cancer care. At #ASCO, see how Haystack MRD brings the clarity behind more confident clinical decisions. Visit the Quest Diagnostics booth 10109 to meet Confidence—the Haystack Hero for #ctDNA testing. Learn more: https://t.co/taagBmE8yl

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

See our poster presentation, “Real-world utilization of molecular residual disease testing in cancer care,” at #ONSCongress today: 11:25 AM–11:35 AM at Tower View Registration, Poster pavilion, Poster monitor 15. #ctDNA #MRD

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Scientific session spotlight at the 2026 ONS Congress: “Real-world utilization of molecular residual disease testing in cancer care,” May 14 from 11:25 AM–11:35 AM at Tower View registration, Poster Pavilion, poster monitor 15. #ctDNA #MRD #ONSCongress

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

From clinical practice to clinical research, Haystack MRD® delivers exceptionally accurate ctDNA detection. See you at COA 2026 in Orlando. https://t.co/8Kl7tMkhLX #COA2026 #MRD #ctDNA

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Visit Quest Diagnostics® booth 808 at COA 2026 to learn how Haystack MRD® supports real-time treatment monitoring. https://t.co/L6oEBFlSVD #COA2026 #MRD #ctDNA

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

We're excited to share that Haystack MRD® by Quest Diagnostics® was featured on CBS News Baltimore! Watch the story here:
https://t.co/4sfOik6Ugz

#ctDNA #MRD #PrecisionOncology

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Biopharma teams: Haystack MRD® can support your oncology trials through ctDNA-guided patient enrichment and stratification. Let’s connect at COA 2026. https://t.co/Tz3424zx3w #COA2026 #MRD #ctDNA

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Oncology professionals—stop by Quest Diagnostics® booth 808 at the 2026 COA conference to explore ctDNA testing options with Haystack MRD®. https://t.co/rdgI3nTNhD #COA2026 #MRD #ctDNA

[Haystack MRD® by Quest Diagnostics® @HaystackMRD]

Haystack MRD® helps clinicians detect recurrence, make treatment decisions, and monitor treatment response. Let’s connect at #COA2026—Quest Diagnostics® booth 808. Learn more: https://t.co/LLlwUigW3c